Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 12/20 | 0.94 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.94 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.94 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine Triphosphate SCHEMBL12636116 | 1.00 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL2778525 | 1.00 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL376210 | 1.00 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL76682 | 1.00 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL76683 | 1.00 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL14976686 | 1.00 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL107380 | 1.00 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL14406726 | 1.00 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL12671699 | 1.00 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL29829840 | 1.00 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779659-B2 | RNA constructs and uses thereof | BioNTech SE (DE) | 2023-10-10 | — | — | US | disclosed |
| US-20230145774-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION | TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20220378876-A1 | Treatment Involving Therapeutic Antibody and Interleukin-2 (IL2) | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2022-12-01 | — | — | US | disclosed |
| US-20220143144-A1 | TREATMENT INVOLVING INTERLEUKIN-2 (IL2) AND INTERFERON (IFN) | TRON- TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378876-A1 | Treatment Involving Therapeutic Antibody and Interleukin-2 (IL2) | IL2, IL2RA, IFNG | P2RY2 1576/4885P2RY4 2780/4885P2RY6 2859/4885 |
| US-11779659-B2 | RNA constructs and uses thereof | RNGTT, RNMT, NSUN3 | P2RY2 2737/4885P2RY4 2760/4885P2RY6 1849/4885 |
| US-20230145774-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION | ICOS, STING1, EIF2AK2 | P2RY2 3948/4885P2RY4 3984/4885P2RY6 3756/4885 |
| US-20220143144-A1 | TREATMENT INVOLVING INTERLEUKIN-2 (IL2) AND INTERFERON (IFN) | IL2, IFNG, IL2RA | P2RY2 459/4885P2RY4 1075/4885P2RY6 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.